Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
NCT ID: NCT02216552 Phase: PHASE2 Status: COMPLETED Enrollment: 10 Completion: 2017-03-20
Conditions
NAFLD, TYPE 2 DIABETES, METABOLIC SYNDROME
Interventions
Resveratrol, Placebo
Summary
The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.
Primary Outcome
Safety/ Adverse Event Outcome